Physician profile
Derek Summers
NPI 1578027843
$1,490.71
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.87 · 2024: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Education: $15.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.18 |
| Education | $15.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.06 | 2023-2024 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $249.80 | 2024 | Tavneos |
| Alexion Pharmaceuticals, INC. | $148.53 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $144.78 | 2024 | |
| Travere Therapeutics, INC. | $130.03 | 2024 | |
| Ardelyx, INC. | $82.00 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.49 | 2024 | Jardiance |
| Vifor Pharma, INC. | $69.55 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $67.09 | 2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $38.28 | 2024 | Acthar |
| Invivyd INC | $33.12 | 2024 | Pemgarda |
| Aurinia Pharma U.S., INC. | $32.90 | 2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $29.78 | 2024 | |
| Lilly USA, LLC | $16.62 | 2023 | Mounjaro |
| Abbvie INC. | $16.20 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $15.53 | 2024 | Rayaldee |
| Novo Nordisk INC | $13.84 | 2023 | Rybelsus, Ozempic |
| Calliditas Therapeutics US INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.